Advertisement

Topics

Imminent Approval of Novartis’ CAR-T Cell Therapy is a Long-awaited Win for the Industry and the World

10:17 EDT 1 Aug 2017 | Synbiobeta

A frontrunner seems to have finally emerged in the race to bring the first CAR-T cell therapy to market.  For several months the two chief competitors and their drug candidates have been Novartis’ tisagenlecleucel-T and Kite Pharma’s axicabtagene ciloleucel, both […]

The post Imminent Approval of Novartis’ CAR-T Cell Therapy is a Long-awaited Win for the Industry and the World appeared first on SynBioBeta.

Original Article: Imminent Approval of Novartis’ CAR-T Cell Therapy is a Long-awaited Win for the Industry and the World

NEXT ARTICLE

More From BioPortfolio on "Imminent Approval of Novartis’ CAR-T Cell Therapy is a Long-awaited Win for the Industry and the World"

Quick Search
Advertisement
 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...